Study of Annexin A2 A valuable Serum Marker for Hepatocellular Carcinoma

Abstract

he aim of this study is to determine the value of serum annexin a2 in the diagnosis of hepatocellular carcinoma in high risk patients (cirrhotic patients) and was conducted on 200 adult individuals. All subjects after them consent & explanation of aim of the work for this study to them were subjected to:- Full history and clinical examination Laboratory investigations that includes:- 1- Complete blood count 2- Liver profile tests 3- Renal function tests 4- HCV: anti HCV antibodies by ELISA 5- Tumour marker: (Measurement of serum alpha,fetoprotein) 6- Assay level of Annexin A2 in serum by ELISA 7- Imaging studies including:- a- Abdominal ultrasonography. b- Triphasic spiral abdominal CT scanning in proved hepatocellular carcinoma patients (as increased serum alpha, fetoprotein).

Subjects were excluded:- Patient who refused to participate in the study. Inflamatory or septic condition as spontaneous bacterial peritonitis. Carcinoma other than HCC. Pregnancy. Findings in the results are susummarized as follows:- In the current study, serum Annexin A2 levels were elevated with statistical significant difference among HCC patients when compared to cirrhotic patients and also serum ANXA2 levels were elevated in cirrhotic patients when compared to healthy adult individuals. Serum ANXA2 levels were elevated with statistical significant difference among HCC patients in terms of advancement with Child-Pugh classification (C) when compared to Child-Pugh (B&A). Serum ANXA2 levels were elevated with statistical significant difference among HCC patients in terms of advancement with MELD Scores (≤9 up to 30-39),but in cirrhotic patients no statistical significant difference between MELD Scores (≤9, 10-19 and 30-39). Serum ANXA2 levels were elevated with statistical significant difference among HCC patients with normal AFP levels (<20 ng/ml) when compared to cirrhotic patients and healthy individuals. Serum ANXA2 levels were elevated with statistical significant difference among HCC patients with elevated AFP levels (>20 ng/ml) when compared to cirrhotic patients. Serum ANXA2 levels were elevated with statistical significant difference among HCC patients whose classified (TNM Stage Ш) when compared to patients whose classified (TNM stages І&ІІ). Serum ANXA2 levels were elevated with statistical significant difference among HCC patients whose classified (BCLC Stages C&D) when compared to patients whose classified (BCLC stages 0, A and B) (P-value =0.001). Serum ANXA2 levels were elevated with statistical significant difference among HCC patients grading (Grade Ш) when compared to patients grading (Grades І&ІІ) . These data suggests that serum ANXA2 may serve as areliable candidate biomarker for diagnosis of HCC. Serum ANXA2 levels were elevated with no statistical significant difference among HCC patients with elevated AFP levels when compared to those with normal AFP levels. This data suggests that serum ANXA2